Data from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors

<div>Abstract<p>Increased PI3K signaling as a result of <i>PIK3CA</i> mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (<i>PTEN</i>) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in <i>PTEN</i>-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in <i>PTEN</i>-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of <i>PTEN</i> knockout and <i>PIK3CA</i>-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of <i>PTEN</i> knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in <i>PTEN</i>-deficient or <i>PI3K</i>-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.</p></div>